Skip to main content
SpringerLink
Log in

Drug Therapy for Rhythm and Rate Control in Atrial Fibrillation

  • Chapter
  • First Online:
Atrial Fibrillation Therapy

Part of the book series: Current Cardiovascular Therapy ((CCT))

  • 1523 Accesses

Abstract

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in clinical practice. It is not a benign disease because is associated to a significant increase in mortality and morbidity. Thus, being AF a potentially dangerous arrhythmia, it seems logical to use antiarrhythmic strategies to avoid, or at least control, this rhythm disturbance [1, 2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation – executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). Eur Heart J. 2006;27:1979–2030.

    Article  PubMed  Google Scholar 

  2. Camm JA, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, DeSutter J, Goette A, Gorenek B, Heldal M, Hohnloser SH, Kolh P, LeHeuzey JY, Ponikowski P, Rutten FR. Guidelines for the management of atrial fibrillation. Eur Heart J. 2010;31:2369–429.

    Article  PubMed  Google Scholar 

  3. Wyse DG, Waldo AL, DiMarco JP. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–32.

    Article  PubMed  CAS  Google Scholar 

  4. Corley SD, Epstein AE, DiMarco JP. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. Circulation. 2004;109:1509.

    Article  PubMed  Google Scholar 

  5. Tsadok MA, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, Humphries KH, Tu JV, Behlouli H, Pilote L. Rhythm versus rate control therapy and subsequent stroke or transient ischemic attack in patients with atrial fibrillation. Circulation. 2012;126:2680–7.

    Article  PubMed  Google Scholar 

  6. Camm AJ, Capucci A, Hohnloser S, Torp-Pedersen C, Van Gelder IC, Mangal B, Beatch GN. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent onset atrial fibrillation. J Am Coll Cardiol. 2011;57:313–21.

    Article  PubMed  Google Scholar 

  7. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Bergmann JF. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2007;4:CD005049.

    PubMed  Google Scholar 

  8. Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T, Oeff M, Seipel L, Trappe HJ, Treese N, Breithardt G. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J. 2004;25:1385–94.

    Article  PubMed  Google Scholar 

  9. Connolly SJ. Evidence-based analysis of amiodarone efficacy and safety. Circulation. 1999;100:2025–34.

    Article  PubMed  CAS  Google Scholar 

  10. Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, Radzik D, Aliot EM, Hohnloser SH. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357:987–99.

    Article  PubMed  CAS  Google Scholar 

  11. Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21:597–607.

    Article  PubMed  Google Scholar 

  12. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668–78.

    Article  PubMed  CAS  Google Scholar 

  13. Kober L, Torp-Pedersen C, McMurray JJ, Gotzsche O, Levy S, Crijns H, Amlie J, Carlsen J. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358:2678–87.

    Article  PubMed  Google Scholar 

  14. Healy JS, Baranchuk A, Crystal E. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45:1832.

    Article  Google Scholar 

  15. Disertori M, Latini R, Barlera S. Valsartan for the prevention of recurrent atrial fibrillation. N Engl J Med. 2009;360:1606.

    Article  PubMed  Google Scholar 

  16. Liu T, Li L, Karantzopoulos PO. Statin use in the development of atrial fibrillation: asystematic review and meta-analysis of randomized clinical trials and observational studies. Int J Cardiol. 2008;126:160.

    Article  PubMed  Google Scholar 

  17. Fauchier L, Pierre B, de Labriolle A, et al. Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2008;51:828.

    Article  PubMed  CAS  Google Scholar 

  18. AFFIRM Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–33.

    Article  Google Scholar 

  19. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, Hillege HL, Bergsma-Kadijk JA, Cornel JH, Kamp O, Tukkie R, Bosker HA, Van Veldhuisen DJ, Van den Berg MP. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362:1363–73.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiology Service, Hospital Parc Tauli de Sabadell, Sabadell, Barcelona, Spain

    Josep Guindo Soldevila MD

  2. Department of Cardiology, University Hospital of Sabadell, Sabadell, Barcelona, Spain

    Antoni Martinez-Rubio MD, PhD, MsHM, FESC, FACC

Authors
  1. Josep Guindo Soldevila MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antoni Martinez-Rubio MD, PhD, MsHM, FESC, FACC
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Josep Guindo Soldevila MD .

Editor information

Editors and Affiliations

  1. Internal Medicine Clinic & Department of Cardiology, Colentina University Hospital, Bucharest, Romania

    Gheorghe-Andrei Dan

  2. Catalan Institute of Cardiovascular Sciences, Hospital Santa Creu i Sant Pau, Barcelona, Spain

    Antoni Bayés de Luna

  3. Cardiovascular Sciences Research, Centre Division of Clinical Sciences,, St. George's University of London, London, United Kingdom

    John Camm

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag London

About this chapter

Cite this chapter

Soldevila, J.G., Martinez-Rubio, A. (2014). Drug Therapy for Rhythm and Rate Control in Atrial Fibrillation. In: Dan, GA., Bayés de Luna, A., Camm, J. (eds) Atrial Fibrillation Therapy. Current Cardiovascular Therapy. Springer, London. https://doi.org/10.1007/978-1-4471-5475-4_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-5475-4_5

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-5474-7

  • Online ISBN: 978-1-4471-5475-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation